О. Л. Барбараш

Safety and immunogenicity of a new formulation of interferon beta-1a (Rebif (R) new formulation) in a phase IIIb study in patients with relapsing multiple sclerosis: 96-week results

James Simsarian, О. Л. Барбараш, F. Casset‐Semanaz et al. · 2008 · 44 citations

Clinical Immunology, New Formulation, Autoimmune Disease +10

ROLE OF CALCIUM-PHOSPHATE BIONS IN PATHOGENESIS OF ATHEROSCLEROSIS: TOXICITY FOR ENDOTHELIUM

Anton G. Kutikhin, Кутихин Антон Геннадьевич, Е. А. Великанова et al. · Perm Medical Journal · 2015 · 17 citations · Full text

Vascular Disease, Pathology, Cell Death +18

Six month results of randomized clinical trial: Multivessel stenting versus staged revascularization for ST-elevation myocardial infarction patients with second generation drug eluting stents

Р. С. Тарасов, V. I. Ganyukov, А. В. Протопопов et al. · 2014 · 15 citations

Randomized Clinical Trial, Endovascular Technique, Multimodality +16